


# SERUM PROTEOMICS OF CMS FIELD OUTBREAK SAMPLES



Moore, L.; Thompson, K.; Costa, J.; Sourd, P.; Bordeianu, A.;  
Chadwick, C.; Moghadam, M.; Brady, N.; Eckersall, D.; del-Pozo, J.

# TALK OUTLINE

- Why biomarkers? / Previous work
- Study design
- Results
- Conclusions and further study



**PMCV**

# WHY BIOMARKERS?

## *Mortality Timing*

Frequently: 2y at sea (pre-harvest)

Recently: 1-7m post-transfer!

## *Mortality pattern*


Protracted/mild mortalities

Sudden outbreaks/severe mortality



**CLINICAL, EPIDEMIOLOGICAL, PATHOLOGICAL DATA SUGGESTS  
SUBCLINICAL CMS IS COMMON IN AFFECTED SITES**  
(i.e. a clinically healthy cage/site with subclinical cases)  
“chronic cardiac patients”

## Mortality Pattern



# WHY BIOMARKERS?

Clinical  
signs  
detection

Ancillary  
testing

Histology &/or  
rtPCR

CMS  
diagnosis

(+ or -)

## ISSUES




Sampling of clinically ill fish  
Late diagnosis > more impact?  
Destructive > smaller sample

## DESIRABLE

- Random subclinical testing
- Early diagnosis, prognostic
- Non destructive > larger sample  
> ↑ sample power

SERUM  
BIOMARKERS

# Proteomic characterization of serum proteins from Atlantic salmon (*Salmo salar* L.) from an outbreak with cardiomyopathy syndrome

Janina Z. Costa<sup>1</sup>  | Jorge del Pozo<sup>2</sup>  | Kevin McLean<sup>3</sup> | Neil Inglis<sup>3</sup> |  
Philippe Sourd<sup>4</sup> | Andrei Bordeianu<sup>4</sup> | Kim D. Thompson<sup>1</sup> 

QUALITATIVE

CLINICAL CMS

Leakage Enzymes	Host Reaction	Regeneration / Remodeling
Creatine kinase	Haptoglobin*	Fibronectin
Lactate dehydrogenase	Fibrinogen*	Lumican
Glycogen phosphorylase	Kininogen*	Retinol-binding*
Carbonic anhydrase	$\alpha_2$ -macroglobulin*	Lipocalin
	Ceruloplasmin*	
	Complement factor B*	
	Serine protease-like	
* = acute phase protein		

---

# STUDY DESCRIPTION




SEMI QUANTITATIVE



SUBCLINICAL CASES

# SEMI- QUANTITATIVE PROTEOMICS (ITRAQ)

- Isobaric tags for relative absolute quantitation of proteins (iTraQ)



# STUDY DESCRIPTION

## Cases and Controls Biobank

- **28 Samples** arranged in 7 iTraQ experiments
- Randomly chosen (large sample set)
- Each experiment
  - Negative control
  - Low PCMV load
  - Medium PCMV load
  - High PCMV load

Subclinical CMS

## iTraQ – Relative Quantification

- Evaluation of common patterns across experiments
- *Relative ratio data*

1- Candidate biomarkers

**Subclinical CMS**

(n=21)

VS

**Healthy**


(n=7)

2-Candidate biomarkers


**PCMV viral load**



# RESULTS



Garseth et al. J Fish Dis **41**: 11-26, 2018




Others


Acute phase proteins (11)

Haemolysis (5)

Leakage proteins (1)


Hypercoagulability





# CONCLUSIONS

- Candidate biomarkers identified
  - Acute phase proteins
  - Hypercoagulability/Haemolysis
  - Leakage biomarkers
  - Other
- Further characterisation required
  - Immunoassay development and diagnostic validation



**PMCV**



# THANK YOU, ANY QUESTIONS?



Kim Thompson



Janina Costa



David Eckersall



Nicola Brady



Philippe Sourd



Andrei Bordeianu



Chris Chadwick



THE UNIVERSITY of EDINBURGH  
The Royal (Dick) School  
of Veterinary Studies



Jorge del Pozo



Benchmark  
Genetics



Hooman Moghadam